TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell

Figure 2

TRIM29 significantly increased the sensitivity of P53 mutant colon cancer cell HT29 to oxaliplatin. (a) HT29 cell growth curve after transfection of pIRES2-ZsGreen1-TRIM29-flag plasmid. (b) HCT116 cell growth curve after transfection of pIRES2-ZsGreen1-TRIM29-flag plasmid. (c) HT29 cell inhibition curve to oxaliplatin after transfection of pIRES2-ZsGreen1-TRIM29-flag plasmid. (d) HCT116 cell inhibition curve to oxaliplatin after transfection of pIRES2-ZsGreen1-TRIM29-flag plasmid. (e) IC50 change of HT29 cells after transfection of pIRES2-ZsGreen1-TRIM29-flag plasmid. (f) IC50 change of HCT116 cells after transfection of pIRES2-ZsGreen1-TRIM29-flag plasmid. ns: no significant; . Comparisons among multiple groups were analyzed by one-way ANOVA, followed by Tukey’s post hoc test. Data among multiple groups in skew distribution were tested by the nonparametric Kruskal–Wallis H test.

(a)

(b)

(c)

(d)

(e)

(f)